Understanding how specific immune receptors affect brain cancer growth
Deciphering TREM1/2 Function in Primary Brain Cancer Using a New Model of Glioblastoma
This study is looking at how two immune receptors, Trem1 and Trem2, affect the body's immune response to glioblastoma, a tough type of brain cancer, and it aims to find new ways to help patients by understanding how these receptors influence tumor growth and treatment resistance.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beth Israel Deaconess Medical Center NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10999313 on NIH RePORTER |
What this research studies
This research investigates the roles of two immune receptors, Trem1 and Trem2, in the context of glioblastoma, a highly aggressive brain cancer. Using a novel mouse model, the study aims to explore how these receptors influence the immune response in the bone marrow when glioblastoma is present. By selectively eliminating these receptors in specific immune cells, researchers will analyze changes in the tumor microenvironment and how this might affect tumor growth and resistance to treatment. The findings could provide insights into new therapeutic strategies for glioblastoma patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with glioblastoma who may benefit from novel immunotherapeutic approaches.
Not a fit: Patients with other types of brain tumors or those who are not diagnosed with glioblastoma may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that enhance the immune response against glioblastoma.
How similar studies have performed: Previous research has shown promising results in targeting immune receptors in cancer treatment, suggesting potential for success in this approach.
Where this research is happening
Boston, United States
- Beth Israel Deaconess Medical Center — Boston, United States (Active)
Researchers
- Principal investigator: Charest, Alain — Beth Israel Deaconess Medical Center
- Study coordinator: Charest, Alain
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.